Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA4 | P22748 | 1/20 | 0.49 |
| ▸ | CA5A | P35218 | 1/20 | 0.49 |
| ▸ | CA7 | P43166 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 5/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17544669 | 0.81 | MAOB (0.49) | CA12CA1CA2CA4CA5A | |
| SCHEMBL943390 | 0.80 | CA12 (0.49) | CA12CA1CA2CA4CA5A | |
| SCHEMBL9264667 | 0.77 | NQO1 (0.50) | CA12CA1CA2CA7CA9 | |
| SCHEMBL16555009 | 0.76 | CD274 (0.54) | — | |
| SCHEMBL10200201 | 0.75 | ALOX5 (0.53) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL509739 | 0.75 | HTT (0.49) | CA1CA2CA9LMNASMN1; SMN2 | |
| SCHEMBL17303853 | 0.74 | MAPT (0.49) | MAOBRAB9ASMN1; SMN2L3MBTL1MAPT | |
| SCHEMBL3332404 | 0.74 | CA12 (0.47) | CA12CA1CA2CA7CA9 | |
| SCHEMBL339813 | 0.73 | LMNA (0.82) | CA12CA1CA2CA4CA5A | |
| SCHEMBL27367676 | 0.73 | LMNA (0.82) | CA12CA1CA2CA4CA5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108690053-A | Heteroaryl compound and its application method | 桑诺维恩药品公司 | 2018-10-23 | — | — | CN | disclosed |
| EP-2925762-B1 | TRIAZOLO-PYRAZINE DERIVATIVES USEFUL IN THE TREATMENT OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM | SUNOVION PHARMACEUTICALS INC (US) | 2017-07-05 | — | — | EP | disclosed |
| US-9670230-B2 | Heteroaryl compounds and methods of use thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2017-06-06 | — | — | US | disclosed |
| US-9670230-B2 | Heteroaryl compounds and methods of use thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2017-06-06 | — | — | US | disclosed |
| CN-105051042-A | Triazolo-pyrazine derivatives useful in the treatment of central nervous system disorders | SUNOVION PHARMACEUTICALS INC | 2015-11-11 | — | — | CN | disclosed |
| US-20150291626-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. | 2015-10-15 | — | — | US | disclosed |
| EP-2925762-A1 | TRIAZOLO-PYRAZINE DERIVATIVES USEFUL IN THE TREATMENT OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM | Sunovion Pharmaceuticals Inc. (US) | 2015-10-07 | — | — | EP | disclosed |
| US-8841327-B2 | Heterocycles substituted pyridine derivatives and antifungal agent containing thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2014-09-23 | — | — | US | disclosed |
| EP-1577288-B1 | Selective estrogen receptor modulators | EISAI R&D MAN CO LTD (JP) | 2014-07-23 | — | — | EP | disclosed |
| WO-2014085284-A1 | TRIAZOLO-PYRAZINE DERIVATIVES USEFUL IN THE TREATMENT OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM | SUNOVION PHARMACEUTICALS INC. (US) | 2014-06-05 | — | — | WO | disclosed |
| EP-1615899-A1 | ALPHA-SUBSTITUTED CARBOXYLIC ACIDS AS PPAR MODULATORS | PFIZER INC. (US) | 2006-01-18 | — | — | EP | disclosed |
| US-20050234066-A1 | Alpha substituted carboxylic acids | AGOURON PHARMACEUTICALS, INC. | 2005-10-20 | — | — | US | disclosed |
| EP-1577288-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS | Eisai Co., Ltd. (JP) | 2005-09-21 | — | — | EP | disclosed |
| US-20050187266-A1 | Alpha substituted carboxylic acids | PFIZER INC | 2005-08-25 | — | — | US | disclosed |
| WO-2004092145-A1 | ALPHA SUBSTITUTED CARBOXYLIC ACID AS PPAR MODULATORS | PFIZER INC. (US) | 2004-10-28 | — | — | WO | disclosed |
| US-5118694-A | Hypotensive agents; treatment for cardiovascular and muscular disorders | HOFFMANN-LA ROCHE INC. (US) | 1992-06-02 | — | — | US | disclosed |
| US-5084458-A | Bactericides, malaria and antitumor agents | SCHAPER KLAUS JUERGEN (DE) | 1992-01-28 | — | — | US | disclosed |
| US-4997835-A | Bactericides, malaria, antitumor | SCHAPER KLAUS JUERGEN (DE) | 1991-03-05 | — | — | US | disclosed |
| US-4971982-A | HYPOTENSIVE AGENTS, CARDIOVASCULAR DISORDERS, SMOOTH MUSCLE DISORDERS | HOFFMANN-LA ROCHE INC. (US) | 1990-11-20 | — | — | US | disclosed |
| US-3952101-A | BETA ADRENERGIC STIMULANT | SMITHKLINE CORPORATION (US) | 1976-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150291626-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | COMT, GPR119, NLN | CA12 4449/4885CA1 4139/4885CA2 4630/4885 |
| US-20050234066-A1 | Alpha substituted carboxylic acids | PPARG, PPARA, PPARD | CA12 4590/4885CA1 4504/4885CA2 3499/4885 |
| US-20050187266-A1 | Alpha substituted carboxylic acids | PPARG, PPARA, PPARD | CA12 4590/4885CA1 4504/4885CA2 3499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.